Related Experiment Video
Updated: Jul 15, 2025

Assays for the Identification of Novel Antivirals against Bluetongue Virus
Published on: October 11, 2013
AMPK inhibitor, compound C, inhibits coronavirus replication in vitro
Minsu Jang1, Rackhyun Park2, Ayane Yamamoto1
1Division of Biological Science and Technology, Yonsei University, Wonju, Republic of Korea.
Abstract:
The coronavirus disease (COVID-19) pandemic has resulted in more than six million deaths by October 2022. Vaccines and antivirals for severe acute respiratory syndrome coronavirus 2 are now available; however, more effective antiviral drugs are required for effective treatment. Here, we report that a potent AMP-activated protein kinase (AMPK) inhibitor, compound C/dorsomorphin, inhibits the replication of the human coronavirus OC43 strain (HCoV-OC43). We examined HCoV-OC43 replication in control and AMPK-knockout (KO) cells and found that the virus replication decreased in AMPK-KO cells. Next, we examined the effect of the AMPK inhibitor, compound C on coronavirus replication. Compound C treatment efficiently inhibited the replication and decreased the coronavirus-induced cytotoxicity, further inhibiting autophagy. In addition, treatment with compound C in combination with chloroquine synergistically inhibited coronavirus replication. These results suggest that compound C can be considered as a potential drug candidate for COVID-19.
Insights
A novel AMPK inhibitor, compound C, effectively suppressed human coronavirus OC43 replication and reduced viral cytotoxicity. This finding suggests compound C as a potential therapeutic for COVID-19 treatment.
Area of Science:
- Virology
- Biochemistry
- Drug Discovery
Background:
- The COVID-19 pandemic caused millions of deaths, necessitating new antiviral therapies.
- Existing vaccines and antivirals for SARS-CoV-2 require complementary treatments.
Purpose of the Study:
- To investigate the antiviral potential of AMP-activated protein kinase (AMPK) inhibitors against human coronavirus OC43 (HCoV-OC43).
- To evaluate compound C as a potential therapeutic agent for coronavirus infections.
Main Methods:
- Examined HCoV-OC43 replication in control and AMPK-knockout cells.
- Assessed the impact of compound C, an AMPK inhibitor, on viral replication and cytotoxicity.
- Investigated the synergistic effect of compound C with chloroquine.
Main Results:
- AMPK knockout cells exhibited reduced HCoV-OC43 replication.
- Compound C significantly inhibited HCoV-OC43 replication and decreased virus-induced cytotoxicity.
- Compound C treatment also inhibited autophagy.
- Combination therapy with compound C and chloroquine showed synergistic antiviral effects.
Conclusions:
- AMPK plays a role in HCoV-OC43 replication.
- Compound C demonstrates potent antiviral activity against HCoV-OC43.
- Compound C is a promising candidate for developing novel COVID-19 therapeutics.
Related Concept Videos
Inhibition of Cdk Activity
cAMP-dependent Protein Kinase Pathways
The Electron Transport Chain
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
Enzyme Inhibition
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...

